ArticleCell host & microbe2026
CBASS limits bacteriophage production while maintaining cell viability in Pseudomonas aeruginosa.
Article in Cell host & microbe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Balancing of immune activation and suppression during phage infection.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Cyclic-oligonucleotide-based anti-phage signaling system (CBASS) is an immune pathway that recognizes phage infection and generates cyclic nucleotide signals, which activate effectors to limit phage replication. Membrane-acting effectors are proposed to induce cell death; however, this mechanism has not been assessed at endogenous effector expression levels. Here, we examine cell viability outcomes of the CBASS phospholipase effector (CapV) upon activation with 3',3'-cGAMP in Pseudomonas aeruginosa. Surprisingly, exogenous 3',3'-cGAMP or constitutive 3',3'-cGAMP signaling from the synthase (CdnA) enables robust cell growth and viability while abolishing phage production. Constitutive activation of the CapV effector induces no cell fitness cost and selectively blocks many phages. During CBASS activation, phage transcription and initial DNA replication proceed normally, but phages do not reach maximum DNA levels and exhibit impaired DNA packaging. We propose that CapV disrupts capsid assembly at the inner membrane, preventing stable phage DNA packaging, thereby allowing effective CBASS anti-viral activity while preserving host viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.